OMDAOmada Health, Inc.

Healthcare

$21.55-5.2% 1Y

$21.55

$10.9452 weeks$26.78

Price

-5.2%1Y

End-of-day closes, not the intraday tick.

A mixed picture: the questions disagree

Quality mixed, nothing alarming, demanding price, growth steady, the market undecided.

What they do

Omada Health, Inc. (together with its subsidiary and consolidated professional corporation, the “Company” or “Omada”) offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal (“MSK”) conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in its cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs.

In the company’s own words · 10-K filed Mar 6, 2026 · SEC EDGAR

P/En/a

Market value$1.12B

1 year-5.2%

5 yearsn/a

Charts

As reported to the SEC, without any scoring.

Omada Health, Inc. (OMDA) reported revenue of $88M in Q2 2026 (quarter ended Jun 30, 2026), up 43% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $5.3M (6.0% of revenue). For the full year FY2025, revenue was $260M (+53% year on year) and net income −$13M. Its largest product in Q2 2026 was Service at $81M, 92% of the disclosed total, well ahead of Hardware at 8.1%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 6, 2026Leadership Transition On August 6, 2026, the Company announced that Sean Duffy, the Company’s current Chief Executive Officer, will become the Company’s Executive Chairman of the Board of Directors (the “Board”), and Wei-Li Shao, the Company’s current President, will succeed Mr. Duffy as the Company’s Chief Executive …Earnings release · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.